{
    "clinical_study": {
        "@rank": "102429", 
        "arm_group": [
            {
                "arm_group_label": "Neridronate", 
                "arm_group_type": "Experimental", 
                "description": "Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Saline solution for infusion: 4 intravenous administrations in a course of 10 days treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether neridronate is effective in the treatment\n      of pain related to bone marrow oedema in patients with osteoarthritis of the knee."
        }, 
        "brief_title": "Efficacy Study of Neridronate to Treat Painful Osteoarthritis of the Knee With Bone Marrow Lesions.", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Osteoarthritis, Knee", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Clinical diagnosis of knee Osteoarthritis (ACR criteria)\n\n          -  Radiographic diagnosis of knee Osteoarthritis (Kellgren/Lawrence scale >=2)\n\n          -  >4 weeks but <3 months pain, reported as >30 mm on a 100 mm VAS scale\n\n          -  bone marrow oedema of the affected knee on magnetic resonance\n\n        Exclusion Criteria:\n\n          -  inflammatory arthritis\n\n          -  aseptic osteonecrosis of the knee\n\n          -  previous or current treatment with Bisphosphonates\n\n          -  serum calcium or creatinine abnormalities"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01803360", 
            "org_study_id": "NERI-OA-2013"
        }, 
        "intervention": {
            "arm_group_label": "Neridronate", 
            "description": "Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment", 
            "intervention_name": "Neridronate", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 13, 2013", 
        "location": {
            "contact": {
                "email": "varenna@gpini.it", 
                "last_name": "Massimo Varenna", 
                "phone": "00390258296897"
            }, 
            "facility": {
                "address": {
                    "city": "Milano", 
                    "country": "Italy", 
                    "state": "MI", 
                    "zip": "20122"
                }, 
                "name": "Istituto Ortopedico Gaetano Pini"
            }, 
            "investigator": {
                "last_name": "Massimo Varenna", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo Controlled Trial to Assess the Efficacy of Neridronate 100 mg -4 i.v. Infusions- in Patients With Painful Osteoarthritis of the Knee With Bone Marrow Lesions.", 
        "overall_contact": {
            "email": "varenna@gpini.it", 
            "last_name": "Massimo Varenna", 
            "phone": "00390258296897"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "to assess the efficacy in terms of proportion of patients with a 50% reduction in pain intensity compared to baseline measured by VAS 100 mm scale recorded at the last visit (day 60)", 
            "measure": "knee pain reduction", 
            "safety_issue": "No", 
            "time_frame": "60 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01803360"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Istituto Ortopedico Gaetano Pini", 
            "investigator_full_name": "Massimo Varenna", 
            "investigator_title": "MD PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Bone marrow lesions reduction", 
            "safety_issue": "No", 
            "time_frame": "60 days"
        }, 
        "source": "Istituto Ortopedico Gaetano Pini", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Istituto Ortopedico Gaetano Pini", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}